---
figid: PMC4264417__fonc-04-00360-g003
figlink: /pmc/articles/PMC4264417/figure/F3/
number: F3
caption: Notch–EGFR crosstalk in TNBC. Dong et al. ascertained a form of crosstalk
  between EGFR and Notch receptors that enabled resistance to EGFR targeted therapy,
  gefitinib, in TNBC cells. It is proposed that EGFR targeted resistance occurs by
  Notch-1-mediated activation of the AKT pathway. Notch–EGFR crosstalk facilitates
  an increase in serine-473 residue phosphorylation of AKT, which allows TNBC cells
  to survive EGFR targeted treatments. Dual inhibition of EGFR via the tyrosine kinase
  inhibitor (TKI) gefitinib and the Notch pathway by GSIs, N-[N- (3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine
  t-butyl ester (DAPT) in vitro, and compound E in vivo, are synergistically lethal
  to TNBC tumorigenesis.
pmcid: PMC4264417
papertitle: Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer.
reftext: Andrew T. Baker, et al. Front Oncol. 2014;4:360.
pmc_ranked_result_index: '130487'
pathway_score: 0.9377133
filename: fonc-04-00360-g003.jpg
figtitle: Notch–EGFR crosstalk in TNBC
year: '2014'
organisms: Homo sapiens
ndex: 0a4960c7-deb1-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4264417__fonc-04-00360-g003.html
  '@type': Dataset
  description: Notch–EGFR crosstalk in TNBC. Dong et al. ascertained a form of crosstalk
    between EGFR and Notch receptors that enabled resistance to EGFR targeted therapy,
    gefitinib, in TNBC cells. It is proposed that EGFR targeted resistance occurs
    by Notch-1-mediated activation of the AKT pathway. Notch–EGFR crosstalk facilitates
    an increase in serine-473 residue phosphorylation of AKT, which allows TNBC cells
    to survive EGFR targeted treatments. Dual inhibition of EGFR via the tyrosine
    kinase inhibitor (TKI) gefitinib and the Notch pathway by GSIs, N-[N- (3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine
    t-butyl ester (DAPT) in vitro, and compound E in vivo, are synergistically lethal
    to TNBC tumorigenesis.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RBPJ
  - AKT2
  - AKT3
  - THRB
  - EGFR
  - ERBB2
  - TYR
  - NOTCH1
  - EP300
  - AKT1
  - EGF
  - THRA
  - Ser
  - Thr
  - Tyr
genes:
- word: CBF-1
  symbol: CBF1
  source: hgnc_alias_symbol
  hgnc_symbol: RBPJ
  entrez: '3516'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Thr
  symbol: THR
  source: bioentities_symbol
  hgnc_symbol: THRB
  entrez: '7068'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: Tyr
  symbol: TYR
  source: hgnc_symbol
  hgnc_symbol: TYR
  entrez: '7299'
- word: '|Notch-1'
  symbol: NOTCH1
  source: hgnc_symbol
  hgnc_symbol: NOTCH1
  entrez: '4851'
- word: p300
  symbol: p300
  source: hgnc_alias_symbol
  hgnc_symbol: EP300
  entrez: '2033'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: Thr
  symbol: THR
  source: bioentities_symbol
  hgnc_symbol: THRA
  entrez: '7067'
chemicals:
- word: Ser
  source: MESH
  identifier: D012694
- word: Thr
  source: MESH
  identifier: D013912
- word: Tyr
  source: MESH
  identifier: D014443
diseases: []
figid_alias: PMC4264417__F3
redirect_from: /figures/PMC4264417__F3
figtype: Figure
---
